Neuropharmacologic evaluation of 2-phenylimidazo-[1,2-a] pyrimidine hydrobromide (U-13,376B), an unusual strychnine antagonist.
D000200:Action Potentials / Q000187:drug effects; D000758:Anesthesia; D000818:Animals; D001337:Autonomic Agents / Q000494:pharmacology*; D002415:Cats; D002421:Caudate Nucleus / Q000187:drug effects; D002698:Chloralose; D003655:Decerebrate State; D004336:Drug Antagonism; D004569:Electroencephalography; D004597:Electroshock; D007093:Imidazoles / Q000494:pharmacology* / Q000633:toxicity; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D010243:Paralysis; D010433:Pentylenetetrazole / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology* / Q000633:toxicity; D011817:Rabbits; D012018:Reflex / Q000187:drug effects; D012121:Respiration, Artificial; D012640:Seizures / Q000139:chemically induced; D013116:Spinal Cord / Q000187:drug effects; D013268:Stimulation, Chemical; D013331:Strychnine / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D015049:Zoxazolamine / Q000494:pharmacology / Q000633:toxicity
D001337:Autonomic Agents; D007093:Imidazoles; D011743:Pyrimidines; D002698:Chloralose; D015049:Zoxazolamine; D013331:Strychnine; D010433:Pentylenetetrazole